Ipsen delivers solid sales growth year-to-date

French drugmaker Ipsen (Euronext: IPN) has presented its sales performance for the year-to-date 2023.

Total sales for the nine months rose 4.6% to 2.31 billion euros ($2.44 billion), or 7.1% at constant exchange rates.

Within this, oncology product revenues down 1.3% at 1.74 billion euros (+0.8% at CER). Neurosciences sales shot up 19.9% to 489 million euros (+24.5% at CER), and rare diseases sales were unchanged at 76 million euros.